Marinomed Biotech entwickelt Produkte im Bereich Atemwegs- und Augenerkrankungen, die auf einer patentgeschützten Technologieplattformen basieren. Der Firmensitz des Unternehmen befindet sich Korneuburg in der Nähe von Wien.

COMPANY

Marinomed Biotech

INVESTOR TERMSHEET

#BGFL app

#BGFL Publisher

93Z

Marinomed Biotech

#BGFL Mood: Neutral · #BGFL-Indicator: Hold · Review date: -

LEI: 529900GN3B1EN80XF405

SECTOR: Gesundheit SUB-SECTOR: Biotechnologie

NAME

Marinomed Biotech

WKN

A2N9MM

ISIN

ATMARINOMED6

TICKER

MBG

INDEX

EXCHANGE

Frankfurt

BUY SELL

Made with ❤ von BGFL

#BGFL

Newswire

Ratings

#BGFL-nes Marinomed Biotech: boersengefluester.de (BGFL) regularly writes extensive editorial articles for most of the companies in our database - especially those in the special stocks sector. Here we show you a list of the most recent articles by BGFL on the selected share.

23.05.2022	Marinomed Biotech: Erhebliches Potenzial
04.05.2021	Marinomed Biotech: Aktie mit ausgeprägter Fanbasis

Newswire Marinomed Biotech: Official company news is an enormously important source of information for investors - especially if it is particularly price-sensitive and therefore subject to ad hoc disclosure. Here we show the reports provided by the IR portal EQS News on companies from the BGFL coverage universe.

19.12.2024	EQS-News: Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
17.12.2024	EQS-News: Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
05.12.2024	EQS-Adhoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
27.11.2024	EQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
27.11.2024	EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares

Resaerch for Marinomed Biotech: Independent research is hard to find, especially in the speciality stocks sector. However, there are a number of firms that regularly produce meaningful analyses of the companies they cover. As a rule, this is paid research - but the analyses are definitely worth reading.

No data

The #BGFL Coverage App Gallery

Visualisation of financial information has been one of boersengefluester.de's (BGFL) favourite disciplines from the very beginning. For this reason, we also put a lot of effort into maintaining our own database and have developed numerous analysis tools and key figure tables on this basis.

Corporate Name Change

Financial Calendar

Interviews, Quotes, Analyses

IR-Quick Check

Annual Reports

Does news drive share prices or does the chain of effects run the other way round - as is often assumed? Well, at boersengefluester.de we offer you all kinds of ways to follow daily stock market events. Take a look at our apps on the subject of news.

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

Marinomed Biotech

Quick Links

Network

Partner

Contact

Marinomed Biotech

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact